Subcutaneous Immunoglobulin 16.5% (Cutaquig) in Primary Immunodeficiency Disease: Safety, Efficacy, and Patient Satisfaction with Modified Dosing Regimens

Authors
Category Primary study
JournalClinical Immunology
Year 2023
This article has no abstract
Epistemonikos ID: 9ad9a64ec2906d4f2934017c5a52400ea6bbe4f4
First added on: Feb 15, 2025